Marloes Hagen

CTA at MICREOS - Den Haag, Zuid Holla, NL

Marloes Hagen's Colleagues at MICREOS
Dominique Meijer

Scientist Drug Substance Development

Contact Dominique Meijer

Bob Rooij

Director Pre-Clinical Operations

Contact Bob Rooij

Maurice Selman

Analytical Method Development Lead

Contact Maurice Selman

Martin Stigter

Method development analist

Contact Martin Stigter

View All Marloes Hagen's Colleagues
Marloes Hagen's Contact Details
HQ
N/A
Location
Hilversum,Noord-Holland,Netherlands
Company
MICREOS
Marloes Hagen's Company Details
MICREOS logo, MICREOS contact details

MICREOS

Den Haag, Zuid Holla, NL • 100 - 249 Employees
BioTech/Drugs

According to the World Health Organization (WHO) emergence of antibiotic-resistant 'superbugs' is now a global concern, which can spell the end of modern medicine and a return to the days when routine operations, simple wounds or straightforward infections were potentially life-threatening. On the other hand scientists have come to realize that the vast majority of bacteria is beneficial and should be left intact. Antibiotics do not distinguish between bad and good bacteria and their use can lead to side effects and resistance. Micreos develops the world's first targeted antibacterial products, set to replace antibiotics. With Micreos' endolysin technology, for the first time it is possible to kill only the unwanted bacteria - including antibiotic resistant strains such as MRSA - while leaving our microbiome - comprising billions of beneficial bacteria on our skin and in our gut - intact. In addition, research shows that the use of endolysins does not induce resistance. This unlocks a completely new approach in dealing with the bacteria around us: killing the bad bacteria and preserving the microbiome. Micreos' Staphefekt SA.100 is an enzyme (endolysin), that targets only Staphylococcus aureus. Marketed under the Gladskin brand, it is the world's first endolysin registered for human use and has had a life-changing impact for thousands of people suffering from inflammatory skin conditions such as eczema, inflammatory acne and rosacea and resistant wound infections (see www.gladskin.com). A series of pharmaceutical products based on the endolysin XZ.700 - also targeting S. aureus - is in clinical development. First indications include: atopic dermatitis, diabetic wound infections and folliculitis. Micreos has also developed FDA-approved food safety products: 'Phageguard S' against Salmonella and 'Phageguard L' against Listeria monocytogenes, which is especially dangerous for pregnant women and for the elderly and immuno-compromised (www.phageguard.com).

Research & Development Product introduction World class phage production Contract manufacturing Phage Technology Endolysin Technology Phage production Endolysin Production Microbiome Staphylococcus aureus MRSA Human Health Dermatology Eczema Rosacea Acne Folliculitis Diabetic Wound Infections Food Safety Listeria Salmonella Intracellular Staph Phageguard Gladskin
Details about MICREOS
Frequently Asked Questions about Marloes Hagen
Marloes Hagen currently works for MICREOS.
Marloes Hagen's role at MICREOS is CTA.
Marloes Hagen's email address is ***@micreos.com. To view Marloes Hagen's full email address, please signup to ConnectPlex.
Marloes Hagen works in the Research industry.
Marloes Hagen's colleagues at MICREOS are Dominique Meijer, Bob Rooij, Maurice Selman, Fabienne Arn, Thalia Harmans, Martin Stigter, Anouk Schans and others.
Marloes Hagen's phone number is N/A
See more information about Marloes Hagen